NASDAQ:NAMS NewAmsterdam Pharma Q1 2025 Earnings Results & Report $20.14 +0.17 (+0.85%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$20.14 0.00 (-0.02%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. NewAmsterdam Pharma missed analyst earnings expectations but beat on revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.49 versus the -$0.45 consensus estimate, while revenue of $2.98 million topped the $1.46 million estimate by $1.52 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call8:00 AM ET NewAmsterdam Pharma EPS ResultsActual EPS-$0.49Consensus EPS -$0.45Beat/MissMissed by -$0.04One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersNewAmsterdam Pharma Revenue ResultsActual Revenue$2.98 millionExpected Revenue$1.46 millionBeat/MissBeat by +$1.52 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) NewAmsterdam Pharma Q1 2025 Earnings FAQ Did NewAmsterdam Pharma beat earnings estimates for Q1 2025? NewAmsterdam Pharma (NASDAQ:NAMS) reported earnings of -$0.49 per share for Q1 2025, missing the consensus estimate of -$0.45. The report was announced on Thursday, May 8, 2025. What was NewAmsterdam Pharma's revenue for Q1 2025? NewAmsterdam Pharma reported revenue of $2.98 million for Q1 2025, against a consensus estimate of $1.46 million. NewAmsterdam Pharma Earnings HeadlinesCantor Fitzgerald Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)November 12 at 9:28 AM | theglobeandmail.comWhat is HC Wainwright's Estimate for NAMS FY2026 Earnings?November 12 at 1:43 AM | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 14 at 1:00 AM | Profits Run (Ad)NewAmsterdam Pharma (NASDAQ:NAMS) Stock Gets Price Target Trim from Needham & Company LLCNovember 8, 2026 | americanbankingnews.comRBC Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)November 6, 2026 | theglobeandmail.comBMO Capital Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)November 6, 2026 | theglobeandmail.comSee More NewAmsterdam Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NewAmsterdam Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your email. Email Address About NewAmsterdam PharmaNewAmsterdam Pharma (NASDAQ:NAMS) is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment. Obicetrapib is investigational, and its development program centers on potential use alongside standard cholesterol-lowering therapies. The company is headquartered in the Netherlands and is led by Chief Executive Officer Michael Davidson. Its research and clinical development work is aimed at addressing unmet needs in cholesterol management and cardiovascular health.View NewAmsterdam Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
